Bio4t2 is at the forefront of developing innovative chimeric antigen receptor T cell (CAR-T) therapies specifically designed to target solid tumors. Utilizing their proprietary PrismCore™ platform, the company genetically modifies T cells to express CARs that are finely tuned to recognize self-antigens overexpressed on cancer cells. This technology employs algorithmic learning and biological observations to create CAR-T cells that activate based on the density of the target antigens, allowing for a precise attack on cancer cells while sparing normal tissues. Additionally, Bio4t2's Bio-Engine™ technology enhances the persistence of CAR-T cells post-infusion, eliminating the need for preparative chemotherapy, which is traditionally required before such treatments. This advancement not only improves patient outcomes but also simplifies the treatment process.

Furthermore, Bio4t2 has developed the Bio-Strike™ technology, which incorporates a safety switch into the CAR-T cells. This switch can be activated by an infused antibody, leading to the rapid destruction of the CAR-T cells if necessary, thereby safeguarding patient wellbeing. The company’s lead product, B4t2-001, is currently undergoing clinical trials and targets the BT-001 antigen, prevalent in various invasive cancers. Bio4t2 is also advancing its pipeline with the development of Bi-CAR-T therapies, which can target two antigens simultaneously, thereby broadening the range of treatable solid tumors and reducing the risk of antigen-negative relapses. These technologies collectively position Bio4t2 as a pioneer in the field of CAR-T therapy for solid tumors.

United States

Bio4t2 is a clinical stage bio pharmaceutical company developing novel single-target and combo-therapeutic CAR based cell therapies against solid cancers through its proprietary PrismCore platform that are fine-tuned to comprehensively target self-antigens in patients with solid tumors.

Bio4t2

Company Details